Authors


Alan S. Brown

Latest:

Hypertriglyceridemia in Connection to FCS

Alan S. Brown, MD, FNLA, FACC, FAHA is a Cardiologist at Advocate Lutheran General Hospital and the President-Elect of the National Lipid Association (NLA). While at the NLA’s 2018 Scientific Sessions in Las Vegas, Nevada, he explained the connection between hypertriglyceridemia and FCS.



Thelma King Thiel

Latest:

Spread the News: Liver Cancer is Preventable

Here's how our understanding of Liver Cancer is changing.


Frank Domino, MD

Latest:

Oral Morphine Versus Ibuprofen to Manage Post-fracture Pain in Children

Is orally administered morphine superior to ibuprofen for outpatient pain management for children with uncomplicated fractures?





Frederick A. Masoudi, MD

Latest:

Medication nonadherence and adverse outcomes in CAD patients

Nonadherence to beta blockers, statins, or angiotensin-converting enzyme inhibitors is common (21%-29%) among patients with coronary artery disease (CAD). Patients who do not adhere to their medication regimens are at increased risk of mortality, cardiovascular hospitalizations, and revascularization procedures; thus, medication nonadherence should be a target for quality improvement interventions to maximize the outcomes of CAD patients.


Aleksandr Rovner, MD: From the Department of Medicine

Latest:

Predicting survival in elderly patients with heart failure

Over a period of 14 years, we followed 282 patients aged 70 years or older who were hospitalized with heart failure. Median survival was 2.5 years, but 25% of patients died within 1 year, and 25% survived for at least 5 years following hospital discharge. A simple 7-item risk score based on data readily available at the time of hospitalization effectively stratified patients into low-, intermediate-, and high-risk categories for subsequent mortality.






Matthew Mahady

Latest:

Flash Findings: Cancer Facts

A collection of cancer statistics and facts



Zelia R. Budhan, MD

Latest:

MI and Ischemic Heart Disease in Overweight and Obesity

A review of the relationship between body mass index, metabolic syndrome, and cardiovascular disease and all-cause mortality.



Javaid Rashid, MD

Latest:

Tardive Dyskinesia: Clues to the Diagnosis and Treatment

Tardive dyskinesia is a common problem associated with the long-term use of potent antipsychotic drugs. It has become less common with the increased use of the newer atypical antipsychotic medications. The condition is manifested by abnormal orofacial, extremity, and sometimes trunk movements. Decades after it was first identified, our understanding of the pathophysiology of tardive dyskinesia remains incomplete, and currently no definitive treatment is available. Encouraging advances in recent years point to promising new treatment options. This article discusses factors that may predispose to tardive dyskinesia as well as the latest developments in treatment.


John S. Rumsfeld, MD, PhD1

Latest:

Incidence of death and MI associated with stopping clopidogrel after ACS

Rates of death and myocardial infarction were assessed for a national sample of acute coronary syndrome patients after stopping clopidogrel. In the first 90 days after stopping treatment, patients experienced a nearly twofold increased risk of adverse events compared with subsequent follow-up intervals for patients treated medically without stents and for patients treated with coronary stents. This suggests a possible clopidogrel rebound effect, but additional studies are needed to support this hypothesis and to identify strategies to reduce early events after clopidogrel cessation.



Dennie V. Jones, Jr, M

Latest:

Hedgehog Signal Inhibition Hope or Hype?

Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.


Richard E. Stewart, MD, is clinical associate professor of medicine, St. Louis University, St. Louis, Missouri.

Latest:

The clinical ramifications of CIBIS III: Does the sequence of medication initiation really matter?

The development of new and innovative mechanical and pharmacologic therapies for the broad spectrum of cardiovascular disease has led to dramatic changes in the makeup of clinical practice.





Doris Day, MD

Latest:

The Impact of Pollution on The Skin

A Lenox Hill Hospital dermatologist outlines the threats surrounding, and ideal therapies for, dermatological conditions brought on by pollution.


Charlotte DeLeo, MD, Frank J. Domino, MD

Latest:

The Real Risks of Sitting

This study was a meta-analysis that examined the association between sedentary behavior and hospitalizations, all-cause mortality, cardiovascular disease, diabetes and cancer in adults.



Miguel Gomez

Latest:

Chronic Leg Ulcer in a Middle-Aged Man

A 60-year-old gentleman presented to a clinic with a large ulceration over his left tibia. The wound was friable, erythematous, and purulent, with necrotic involvement of the tibial tendon sheath. He reports that the lesion started 15 years ago and worsened after surgical debridement 10 years ago. High-dose prednisone helped in the past, but other medications have been of no help. Recently, the patient developed intense pain with occasional fevers, chills, and night sweats. He has type 2 diabetes mellitus, but denies any history of bowel difficulties, hepatitis, or arthralgias. What is your diagnosis?


Peter Buttrick, MD, is professor

Latest:

White-coat hypertension and the development of sustained hypertension

For 50 years, hypertension has been recognized as the most significant risk factor for the development of symptomatic cardiovascular disease in Western society.

© 2024 MJH Life Sciences

All rights reserved.